Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does BASILIXIMAB Cause Drug resistance? 110 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 110 reports of Drug resistance have been filed in association with BASILIXIMAB (Simulect). This represents 1.6% of all adverse event reports for BASILIXIMAB.

110
Reports of Drug resistance with BASILIXIMAB
1.6%
of all BASILIXIMAB reports
24
Deaths
45
Hospitalizations

How Dangerous Is Drug resistance From BASILIXIMAB?

Of the 110 reports, 24 (21.8%) resulted in death, 45 (40.9%) required hospitalization, and 10 (9.1%) were considered life-threatening.

Is Drug resistance Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for BASILIXIMAB. However, 110 reports have been filed with the FAERS database.

What Other Side Effects Does BASILIXIMAB Cause?

Cytomegalovirus infection (590) Drug ineffective (567) Off label use (567) Transplant rejection (554) Kidney transplant rejection (456) Product use in unapproved indication (428) Pyrexia (323) Diarrhoea (314) Multiple organ dysfunction syndrome (298) Polyomavirus-associated nephropathy (298)

What Other Drugs Cause Drug resistance?

LAMIVUDINE (1,889) IMATINIB (1,293) GEFITINIB (1,228) OSIMERTINIB (1,026) NEVIRAPINE (862) PREDNISONE (833) CYCLOPHOSPHAMIDE (817) LEVETIRACETAM (798) METHOTREXATE (765) TENOFOVIR DISOPROXIL (740)

Which BASILIXIMAB Alternatives Have Lower Drug resistance Risk?

BASILIXIMAB vs BAYER GENUINE ASPIRIN ORIGINAL STRENGTH BASILIXIMAB vs BAZEDOXIFENE\ESTROGENS, CONJUGATED BASILIXIMAB vs BCG VACCINE BASILIXIMAB vs BEBTELOVIMAB BASILIXIMAB vs BECLOMETHASONE

Related Pages

BASILIXIMAB Full Profile All Drug resistance Reports All Drugs Causing Drug resistance BASILIXIMAB Demographics